23 min listen
Moving from Preservation to Restoration with Off-the-Shelf Cell Therapies
FromThe Bio Report
ratings:
Length:
21 minutes
Released:
Aug 4, 2022
Format:
Podcast episode
Description
While cell therapies hold great promise for not only halting the progression of degenerative disease but potentially restoring the body, cost has remained a barrier. Lineage Cell Therapeutics is developing allogenic cell therapies that don’t rely on modifying a patient’s own cells, making them scalable and less costly than autologous ones. At the end of last year, the company entered into a partnership with Genentech to develop and commercialize OpRegen, its experimental cell therapy for dry age-related macular degeneration. We spoke to Brian Culley, CEO of Lineage Cell Therapeutics, about the company’s platform technology for off-the-shelf cell therapies, how its platform works, and what the collaboration with Genentech will do to advance the technology.
Released:
Aug 4, 2022
Format:
Podcast episode
Titles in the series (100)
The Lean Startup Takes Hold in the Life Sciences: The National Science Foundation and the National Institutes of Health, concerned about seeing the science they fund commercialized, have embraced the Lean Startup method as a way to improve the odds of success for new companies. Steve Blank, whose wo... by The Bio Report